Skip to Main Content

Biosimilars Commercialization: Lessons Learned from Adalimumab and Four Necessary Approaches

White Paper|

By Matthew Haynes, Ph.D., Ryan Coe, Ph.D.

This white paper explores the complexities of launching biosimilars in a competitive market. Drawing from the experience of adalimumab biosimilars, the paper identifies critical challenges and strategic responses necessary for success. It outlines four key approaches: predicting market erosion, segmenting markets for preferential access, balancing pricing with patient support services, and tracking patient leakage. These insights are designed to help manufacturers navigate the biosimilar landscape and enhance their commercialization strategies.

Biosimilars Commercialization: Lessons Learned from Adalimumab and Four Necessary Approaches

Please submit the form below to view this resource.

Maximize value across the product and patient journeys. Find out how.